Mixed amphetamine salts: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) No edit summary |
MDElliottMD (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic = mixed amphetamine salts | | generic = mixed amphetamine salts | ||
| brand = Adderall, Adderall XR | | brand = Adderall, Adderall XR | ||
| structure = Amphetamine-white.svg | | structure = Amphetamine-white.svg | ||
| | | classes = Psychostimulant, Amphetamine | ||
| mechanism = Increased production and decreased reuptake of NE and DA | | mechanism = Increased production and decreased reuptake of NE and DA | ||
| uses = Inattention, productivity, | | uses = Inattention, productivity, | ||
| Line 40: | Line 12: | ||
| halflife = | | halflife = | ||
| bioavailability = Oral: ~90% | | bioavailability = Oral: ~90% | ||
| pregnancy = | | pregnancy = Class C | ||
| legal = | | legal = Schedule II Controlled Substance | ||
| intro = | | intro = | ||
| pharmacokinetics = | | pharmacokinetics = | ||
Revision as of 05:10, 11 May 2026
Psychostimulant, Amphetamine
mixed amphetamine salts
Adderall, Adderall XR
Experience
2 personal reports · avg efficacy 90.0/100 · avg side-effect burden 30.0/100 · median use 8 months · median dose 17.5 mg/day · 100% still taking it
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Psychostimulant, Amphetamine
Common uses
- Distractibility4.0n=1
- Excessive daytime sleepiness in shift-work disorder4.0n=1
- Impaired persistent attention4.0n=2
- Cognitive symptoms in chronic illness3.0n=1
- Impulsivity3.0n=1
Pharmacy
Pharmacology
Routes
Oral, primarily
Onset
rapid
Duration
8-14h
Bioavailability
Oral: ~90%
Pregnancy
Class C
Legal status
Schedule II Controlled Substance
Purported mechanism
Increased production and decreased reuptake of NE and DA